The genome of PRRSV-2/Hungary/102/2012 was amplified in five overlapping parts, 123 (similarly to Kvisgaard et al., 2013b) , using the Phusion II HotStart PCR kit (Thermo 124 Table 1 . Primers were designed using Primer3Plus (Untergasser et al., 2007) . PCR fragments 129
were purified from agarose gel slices by the QIAquick Gel Extraction Kit (Qiagen, Hilden, 130 Germany). For determination of both ends of the genome, the 5′ RACE System for Rapid 131
Amplification of cDNA Ends, version 2.0 (Invitrogen, Carlsbad, CA, USA) as well as a 132 forward ORF7 primer (Balka et al., 2008 ) and the T 20 primer were applied. 133
134

Next generation sequencing (NGS) 135
An equimolar mixture of the overlapping PRRSV PCR products was used as template for next 136 generation sequencing. In brief, a DNA library was prepared using the NEBNext® Fast DNA 137 
Phylogenetic analysis 147
PRRSV whole genome sequences in Genbank, including 16 type 1 and 199 type 2 field, 148 vaccine and laboratory strains, were obtained from the continents of Europe, Asia, and North 149 America (n=215, Table 2 ). PRRSV whole genome alignment was done with the MUltiple 150
Sequence Comparison by Log-Expectation (MUSCLE) algorithm (Edgar, 2004) 
in Geneious 151
Pro 6.1.7 using default settings. The evolutionary history was inferred using the Maximum 152
Likelihood method based on the Tamura-Nei model (Tamura and Nei, 1993) . The tree with 153 the highest log likelihood (-266940 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 MEGA6 (Tamura et al., 2013) . 160
Additional type 2 PRRSV ORF5 sequences were added to the database to enlarge total 161 genetic diversity. ORF5 nucleotide sequences were aligned with MUSCLE and phylogeny 162 was determined by maximum likelihood in MEGA as described above. The closest known 163 relatives to PRRSV-2/Hungary/102/2012 were determined by BLAST analysis in Genbank 164 (Altschul et al., 1990) . 165
Recombination analysis of the complete genome was performed with Recombination 166 Analysis Tools (RAT) (Etherington et al., 2005) using the 215 Genbank accessions as 167 references. Insertion-deletion analysis was visualized by the alignment of the Hungarian 168 isolate to the type 2 prototype strain VR2332 (acc. number: EF536003) and to the highly 169 pathogenic Chinese strain CHN-JXA1 (acc. number: EF112445). 170
The distribution of N-glycosylation sites was determined using NetNGlyc 1.0 Server 171 web utility (http://www.cbs.dtu.dk/services/NetNGlyc/). The antigenic regions, T and B cell 172 epitopes were determined as described using an amino acid alignment with the reference 173 strains VR2332, Ch-1a (acc. number:AY032626) and NVSL 97-7895 (acc. number: 174 AY545985) (Diaz et al., 2009; de Lima et al., 2006; Mokhtar et al., 2014; Plagemann et al., 175 2002; Ostrowski et al., 2002; Vashisht et al., 2008; Zhou et al., 2009 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 The phylogenetic analysis of the whole genome of PRRSV-2/Hungary/102/2012 and 196 215 other full PRRSV genomes showed that it was a novel type 2 PRRSV isolate that was 197 phylogenetically close to the progenitor type 2 PRRSV, and not related to VR2332 or 198 Ingelvac PRRSV MLV (Figure 1.) . To exclude the possibility that PRRSV-2/Hungary/102/2012 was a recombination 213 product involving unknown parental viruses or European progeny of the type 2 PRRSV 214
Ingelvac MLV vaccine, a recombination analysis was performed. The RAT analysis showed 215 no evidence of recombination anywhere in the genomes of all 216 whole genome sequences 216 available to us (data not shown). 217 PRRSV-2/Hungary/102/2012 has deletions of 10 amino acids (VR3223 aa 314-323) 218 and 9 amino acids (VR2332 aa 792-800) in the nsp2 that were not present in prototype strain 219 VR2332 or the prototype high pathogenicity Chinese strain JXA1 (Figure 3 ). By contrast, 220 there was a 9 aa insertion in the nsp2 (102HU aa 795-803) that was not present in VR2332 or 221 JXA1. These differences were due to in-frame insertions/deletions at the corresponding 222 coding regions of the genomic RNA (Figure 3) . 223 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60   F  o  r  P  e  e  r  R  e  v  i  e  w  O  n  l  y The antigenic regions (ARs) and glycosylation sites within GP2, GP3, GP4 and GP5 224 proteins of PRRSV-2/Hungary/102/2012 have been analyzed and compared to references 225 VR2332, At least four B cell epitopes or ARs have been inferred within GP2 (de Lima et al., 227 2006; Vanhee et al., 2011) . The presence of two antigenic regions (AR [41] [42] [43] [44] [45] [46] [47] [48] [49] [50] [51] [52] [53] [54] [55] ) 228
were confirmed in both type 1 and type 2 PRRSV, while the presence of AR [92] [93] [94] [95] [96] [97] [98] [99] [100] [101] [102] [103] , and the 229 AR 206-217 were confirmed only in the type 1 prototype strain Lelystad virus (de Lima et al., 230 2006; Vanhee et al., 2011) . However, the two latter regions are conservative between type 1 231 and type 2 viruses, so it is possible that they are recognized as B cell epitopes in the type 2 232 PRRSV strains as well. Only one amino acid (aa) substitution was detected in AR [92] [93] [94] [95] [96] [97] [98] [99] [100] [101] [102] [103] The presence of two T cell epitopes (Díaz et al., 2008) and one B cell epitope (de Lima 250 et al., 2006) were reported within GP4. AR 51-65 is a hypervariable region of GP4; five aa 251 substitutions were detected in that of PRRSV-2/Hungary/102/2012 compared to the GP4 of 252 the reference strains. A putative T cell epitope [7] [8] [9] [10] [11] [12] [13] [14] [15] ) is recognized by MHCII (described 253 in PRRSV strain L-450) (Díaz et al., 2008) . This sequence is very divergent in PRRSV-254 2/Hungary/102/2012, as it contains three aa substitutions in the 9 aa epitope. Tce 170-178 , 255 recognized by MHCI (same reference as in previous sentence), has two aa substitutions in 256 PRRSV-2/Hungary/102/2012 compared to the other strains. While four N-glycosylation sites 257 Figure 4C ). 260
The presence of at least six B cell epitopes (de Lima et al., 2006; Zhou et al., 2009) In case of ORF5 sequences of European type 2 strains they were at least 91% identical to the 285 aforementioned vaccine strain. Our previous results of genetic analysis of a PRRSV Type 2 286 ORF5 sequence from Hungary and a similar one in Slovakia (one of Hungary's neighboring 287 countries) indicated that there are type 2 strains circulating in these countries that are much 288 more distant to Ingelvac PRRS MLV. In this study we described the genetic, and antigenic 289 characteristics of the complete genome of the first European, wild, type 2 isolate, which is 290
clearly not related to Ingelvac PRRS MLV. Moreover, the genome of PRRSV-291 isolates globally, revealed that it is a member of an ancient lineage 1 or lineage 2 cluster 296 whose earliest sequence was reported from Eastern Canada in the early 1990's (Brar et al., 297 2011; Shi et al., 2010b) . 298
Our previous analyses with the use of limited sequences suggested that it might belong 299 to lineage 1 (quite similar to lineage 2) (Stadejek et al., 2014) indicating the importance of 300 using an appropriate, broad-range reference set when genotyping otherwise similar type 2 301 PRRSV strains. 302
The Eastern Canadian origin of both lineages 1 and 2 and their cross-border 303 transmission primarily to the North Central USA (Shi et al., 2010b , Brar et al., 2011 suggests 304 that our Hungarian strain may have become established in eastern Europe following the 305 introduction of pigs or germplasm harboring a PRRSV from these regions within the past 10 306 to 15 years. It then evolved independently for an extended period of time to reach its current 307 level of divergence. As no reliable data are available about pig importation to Hungary from 308 that period, it cannot be excluded that a wild-type 2 PRRSV was introduced elsewhere in the 309 region and then transported to Hungary. that is 95% similar at nucleotide and 97% similar at amino acid level. As the strain analyzed 313 in our study was isolated from a farm located close to the Slovakian border, and since no 314 other related strains from independent locations were present in public and private databases, 315 this virus is the most likely recent ancestor giving rise to the family of isolates including 316 PRRSV-2/Hungary/102/2012, HU12 (DQ366650) and HU21 (EF406336). The latter two 317
isolates from 2005 showed only 3% nucleotide and 1% amino acid differences in comparison 318 to PRRSV-2/Hungary/102/2012. This relatively slow rate of evolution in one of the most 319 variable part of the PRRSV genome might suggest that use of a type 1 modified live vaccine 320 used in the herd to control endemic type 1 PRRSV did not provoke a strong selective pressure 321 against the type 2 isolate. Hence, it remained conserved over a period of at least 7 years. 322
Although nsp2 insertions and deletions were present in the genome compared to 323 JAX1 and VR2332, unusual characteristics of pathogenicity or infectivity were not observed 324 under field conditions. However, exact statements on these parameters can only be given after 325 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 also unlikely that the presence of the three glycosylation sites on GP5 would be just a 379 functionless arbitrary event. Most probably these sites are glycosylated in several 380 combinations on different GP5 molecules that compose a set of glycoforms in the PRRSV-381 2/Hungary/102/2012 envelope similarly as it was shown in the VR2332 virion (Thaa et al., 382 2013) . Alternatively, it cannot be excluded that glycosylation patterns are not under selection, 383 but instead are derivative to changes in ORF5a (Robinson et al., 2013) . 384
As a large majority of the amino acid alterations in GP4 and GP5 of our isolate were 385 found in the previously described antigenic regions, we hypothesize that immunological 386 pressure played an important role in the evolution of the virus. It is possible that an early, fast 387 evolution period might have occurred in the early 2000's when an exponential increase in 388 genetic diversity has been observed among type 2 strains (Shi et al. 2010b) . Similar strains 389
were first identified in 2005 by our research team (Balka et al., 2008) , and anecdotal 390 information suggested the import of boars from Canada to the herd in previous years. The 391 comparison of these early strains and the recent isolate revealed the slowing down of the 392 surrounded by other type 2 isolates, and a second slower phase after the virus was introduced 396 to this region, and was not influenced by immunity against other type 2 strains. 397
We conclude that PRRSV-2/Hungary/102/2012 is the first type 2 PRRSV isolated in 398
Europe that belongs to the lineage 1 or 2, and unlike every other European type 2 strain, it is 399 proved to be not related to the Ingelvac MLV. Lineages 1 and 2 were exclusively formed by 400
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